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Tyro sine kinase activity of the EGF receptor in murine
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Tyrosine kinase activity of the EGF receptor in murine metanephric
organ culture. Epidermal growth factor (EGF) and its fetal form, trans-
forming growth factor alpha (TGF-s) are renal mitogens which induce
epithelial hyperplasia, proximal tubular cyst formation (TC), and acceler-
ated distal nephron differentiation in metanephric organ culture. To
delineate the intracellular mechanisms mediating these growth factor
effects, we studied the specific role of the epidermal growth factor receptor
(EGF-R), the common receptor for both ligands, as an activated tyrosine
kinase in TC formation and nephrogenesis. Fetal murine metanephric
explants were incubated for 120 hours in control, and EGF (15 ng/ml)/
TGF-a (10 nglml) supplemented medium with and without EGF-R
blocking monoclonal antibody (50 mg/ml), or tyrosine kinase inhibitor.
EGF-R tyrosine kinase inhibition was achieved by incubation with a
synthetic tyrphostin (TP B42) (0.1 tM) or genestein (5.5 j.rglml). The
following parameters were assessed: (a) segment-specific nephron devel-
opment using morphometry and immunohistology; (b) tubular epithelial
hyperplasia by protein content and BrdU uptake; and (c) TC formation by
morphometric cystic index. Both growth factors produced hyperplastic
proximal TC, significantly increased explant growth, and significantly
increased distal nephron differentiation. Inhibiting the ligand-EGF-R
interaction with EGF-R blocking monoclonal antibody abolished all
growth factor-induced effects and resulted in increased amounts of
undifferentiated mesenchyme and decreased distal nephron differentia-
tion. Inhibition of EGF-R tyrosine kinase activity with either Tyrphostin
B42 or genestein blocked TC formation and produced nodular blastemal
hyperplasia and decreased distal nephron differentiation. Inhibition of
EGF-R tyrosine kinase activity may provide a target for pharmacological
therapy in human cystic disease, in which there are both qualitative and
quantitative abnormalities of EGF-R expression.
Genetically determined human renal cystic diseases are com-
mon disorders causing major morbidity and mortality in all age
groups [1]. Autosomal dominant polycystic kidney disease
(ADPKD) has an incidence of 1:500 to 1:1000 and accounts for
approximately 10 to 12% of all end-stage renal disease in adults
[2]. Autosomal recessive polycystic kidney disease (ARPKD)
occurs in 1 in 16,000 to 1 in 40,000 live births [31, and, along with
nephronophthisis, accounts for 6 to 14% of all end-stage renal
disease in children [4]. Clear delineation of the pathophysiological
mechanisms involved in renal cystogenesis is a prerequisite for the
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development of rational treatment strategies in cystic renal disor-
ders. To date, pathological analysis of renal tissue as well as data
generated from a variety of experimental models have determined
that tubular epithelial hyperplasia is critical to the formation and
growth of large epithelial-lined cysts in cystic renal disorders
[5—7].
Recently, abnormalities in the epidermal growth factor (EGF)/
transforming growth factor alpha (TGF-a)/epidermal growth fac-
tor receptor (EGF-R) axis have been implicated in the processes
of epithelial hyperplasia and experimental renal tubular cyst
formation. Both EGF and TGF-a induce epithelial hyperplasia,
proximal tubular cyst formation, and accelerated distal nephron
differentiation in metanephric organ culture [8], and mediate cyst
formation by normal kidney epithelial cells when cultured in
collagen gel [9].
Enhanced EGF-R tyrosine kinase activity has been associated
with hyperproliferative and transformed states [10]. Following
activation by binding with one of its ligands (EGF or TGF-a), the
EGF-R initiates an intracellular cascade of phosphoiylation
events via its tyrosine kinase activity. Such tyrosine kinase activity
is essential for signal transduction from the cell surface to the
nucleus, resulting ultimately in DNA synthesis and cell division
[11—13]. We therefore sought to determine the specific role of the
EGF-R as a tyrosine kinase in mediating the cystogenic and
maturational actions of EGF and TGF- during nephrogenesis in
murine metanephric organ culture.
Methods
Metanephric organ culture
Our basic method of serum-free culture of the fetal mouse
metanephros has been previously described in detail [14—16].
Briefly, intact metanephroi from Swiss Webster albino mouse
embryos (13 0.4 days gestation) were cultured in chemically
defined medium for 120 hours in a Trowell-type organ culture
assembly at 36 0.5°C and 95% humidity in a mixed air-5% CO2
environment. Basal medium consisted of equal volumes of Dul-
becco's modified Eagle's medium and Ham's F-12 medium sup-
plemented with selenium (6.8 X i0 M), triiodothyronine (2 X
iO M), insulin (8.3 X iO M), transferrin (6.2 x 10—8 M) and
prostaglandin E1 (7.1 X 108 M). Growth factor-supplemented
medium consisted of the basal medium to which either EGF
(15 ng per ml culture medium) or TGF-a (10 ng per ml culture
medium) was added. These concentrations were determined from
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preliminary organ culture/dose-response experiments which de-
lineated the optimal concentrations of each growth factor produc-
ing maximal biological effects without tissue injury [8].
In all experiments, culture medium was replaced with fresh
medium every 24 to 48 hours. All basal culture medium was
obtained from Sigma (St. Louis, MO, USA). Hormones were
obtained as lyophilized tissue culture reagents from Sigma. EGF
was obtained from Gibco (Grand Island, NY, USA; source-mouse
salivary gland) and TGF-a was obtained from Upstate Biotech-
nology, Inc. (Lake Placid, NY, USA; source-human recombinant).
EGF-R inhibition
The effects of inhibition of ligand binding to the EGF-R were
studied utilizing a monoclonal antibody which, in previous in vitro
studies, competitively blocked ligand-EGF-R interaction [17].
The antibody was generated by harvesting supernatant from a
hybridoma cell line and purifying the monoclonal antibody by
elution from a column which specifically binds IgG. American
Type Culture Collection (Rockville, MD, USA) cell line 8506
(human epidermoid carcinoma:mouse spleen hybridoma) was
cultured in RPMI medium containing 10% fetal bovine serum
(Sigma). Supernatant was collected and frozen in 1 M Tris, pH 8
at a ratio of one part buffer to 20 parts supernatant. Samples were
later thawed, washed with RPMI medium, and eluted on a Protein
G Sepharose 4 FF column (Pharmacia LKB Biotechnology, Inc.,
Piscataway, NJ, USA). Antibody fractions were collected in 2 ml
aliquots and those containing monoclonal IgG were identified by
protein content as determined by the Bradford protein microassay
[18]. Antibody was concentrated by centrifugation in Centricon
100 Concentrators (Amicon, Beverly, MA, USA) at 3500 rpm for
30 minutes at 4°C. This process was repeated until the antibody
protein concentration increased at least 10-fold compared to the
original antibody protein concentration eluted from the column.
The final concentration of EGF-R blocking monoclonal antibody
used in all organ culture experiments was 50 mg/ml media. This
concentration was determined by preliminary organ culture/dose-
response experiments which delineated the optimal concentration
of EGF-R antibody required to block cyst formation while minimiz-
ing any toxic epithelial effects (assessed by standard morphologic
methods).
125Jbinding assay
In order to assess the blocking potential of monoclonal anti-
body 8506 specifically in the metanephric organ culture system, a
ligand binding assay was performed according to the method of
Breyer, Redha and Breyer [19]. 1251-EGF labeled to a specific
activity of 100 j.Ci/g of EGF was purchased from AmershamTM
Life Science Inc. Explants cultured for 96 hours in basal medium
were washed 3 X in 37°C PBS then pre-incubated for 30 minutes
in binding medium (DMEM containing 20 mM Hepes and 0.2%
BSA) at 37°C. Basal explants were pre-incubated in binding
medium alone, antibody treated explants were pre-incubated in
binding medium containing anti EGF-R (50 mg/mI), and TM
treated explants were pre-incubated with binding medium con-
taining TYR B42 (0.1 M). Following pre-treatment, explants were
washed 3 X in 4°C PBS then incubated in fresh pre-incubation
medium containing 'I-EGF (5 ng/ml) for 4 hours at 4°C.
(Incubation of ligand at 4°C prevents internalization of the
receptor.) Nonspecific binding was determined by addition of 500
ng/ml of unlabeled EGF. Explants were then washed 3 X in 4°C
PBS and dissolved in 1 N NaOH overnight at 4°C. Radioactivity
was counted in a Beckman 5000 G gamma counter. Specific
binding is defined as the difference between total binding (125I
EGF) and nonspecific binding ('251-EGF plus 100-fold excess
unlabeled EGF). Samples included four explants per group, and
were assayed in triplicate and normalized per sg of protein.
In all organ culture experiments, EGF-R antibody was added to
the organ culture media on the first day of culture and with all
media changes.
EGF-R lyrosine kinase inhibition
The effects of specific inhibition of tyrosine kinase activity was
studied utilizing a series of tyrphostins, chemically synthesized
erbstatin analogues which specifically inhibit protein tyrosine
kinase activity of various growth factor receptors. Tyrphostins
specific for the EGF-R protein tyrosine kinase have been shown
to inhibit EGF-R autophosphorylation as well as EGF-dependent
protein phosphorylation of intracellular substrates resulting in
inhibition of cell proliferation [20-23]. Tyrphostins used in this
study were, Tyrphostin 1, a negative control which has no biolog-
ical effect, and Tyrphostin B42, a potent inhibitor of EGF-R
autophosphorylation. All tyrphostins were obtained from Calbio-
chem (San Diego, CA, USA) as lyophilized powders which were
resuspended in 95% ethanol and stored a —20°C. Genestein, a
competitive inhibitor of ATP and noncompetitive inhibitor of
EGF-R intracellular substrate, was also used [18]. Genestein was
obtained from Upstate Biotechnology, Inc. These synthetic ana-
logues were used at concentrations equivalent to the IC50 for each
compound's most specific site of tyrosine kinase inhibition (that is,
EGF-R autophosphorylation or intracellular substrate phosphor-
ylation).
The effectiveness of tyrosine kinase inhibition activity was
assessed by Western analysis of EGF-R autophosphorylation
following treatment of explants with anti-EGF-R (50 mglml) or
Tyrphostin B42 by modifications of the methods of Donaldson
and Cohen [24] and Honegger et al [25]. Briefly, following
incubation under basal conditions for 96 hours, explants were
washed with ice cold PBS 2X for five minutes. Four groups of
explants were then incubated with ice cold medium containing:
(a) basal medium; (b) basal medium + 15 ng/ml of EGF; (c) basal
medium + anti-EGF-R (50 mg/mI) + 15 ng/M EGF); and (d)
basal medium + Tyrphostin B42 (0.1 LM) + 15 ng/ml EGF, for
four hours at 4°C. (Incubation at 4°C prevents internalization of
the receptor while allowing autophosphorylation.) Explants were
then homogenized in ice-cold RIPA buffer (containing protease
inhibitors) and cellular debris was pelleted by centrifugation. The
supernatant was transferred to clean conical microfuge tubes,
protein content determined and equal amounts of total protein
was incubated with 4.0 g of anti EGF-R (RK-2) for 2 hours at
4°C. Supernatant samples were then incubated with 25 p.l of
Protein A/G PLUS-Agrose (Santa Cruz Biotechnology, Inc.) at
4°C on a rocker platform overnight. Immunoprecipates were
collected by centrifugation, pellets washed 2>< with 1 ml of RIPA
buffer and resuspended in 50 .tl of RIPA buffer containing
protease inhibitors and 40 l of suspension mixed with 10 uJ of 5 X
Lamelli's sample buffer and boiled for 5 minutes. Immunoprecipi-
tates were stored at —70°C until resolved under reducing condi-
tions on 7.5% SDS-PAGE. Gels were loaded with equal protein
content per lane for SDS-PAGE, electrophoretically transferred
to nitrocellulose and probed with anti phosphotyrosine (PY-20,
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Table 1. Experimental groups
Medium Additives
1 basal None
2 basal EGF
3 basal TGF-a
4 basal Anti-EGF-R
5 basal EGF + anti-EGF-R
6 basal TGF-a + anti-EGF-R
7 basal Tyrphostin 1
8 basal EGF + Tiyphostin 1
9 basal TGF-a + Tryphostin 1
10 basal Tiyphostin B42
11 basal EGF + Tryphostin B42
12 basal TGF-a + Tryphostin B42
13 basal Genestein
14 basal EGF + Genestein
15 basal TGF-a + Genestein
Transduction Laboratories) and detected by ECL (Amersham
Life Science). Equal loading of gels was confirmed by Ponseau S
staining of the blot.
In all organ culture experiments, tyrphostins were added to the
organ culture medium on the first day of culture and with all
media changes. Genestein was added to culture medium for 2
hour pulses at 24, 48, 72, and 96 hours of culture. The genestein-
containing media was then removed and the explants were
"washed" with fresh media and incubated between genestein
pulses with basal media.
The growth factor supplementation and EGF-R inhibition
protocols were divided into 15 experimental groups for analysis
(Table 1).
Determination of cystic index
The degree of proximal tubular cyst formation was quantitated
by utilization of a cystic index. The index has been derived from
basic light morphometric methods [26] and has been standardized
as a tool for quantitation of cyst formation in organ culture
systems [27, 28]. Following routine histologic preparation (see
below), 8 to 10 serial 3 M sections of intact explants were graded
for cyst formation in Lotus tetragonolobus -positive tubular seg-
ments on a scale of 0 (no observable cysts) through 4 (multiple
cysts larger than 0.20 mm) [27, 28]. For each treatment group, a
cystic index was determined on a total of six to eight explants
following 120 hours of incubation.
Determination of growth and tubular hyperplasia
Growth of metanephric explants was assessed for control and
each experimental group following 120 hours of incubation using
the Bradford protein microassay [18]. Explant viability was as-
sessed using previously described methods of cellular trypan blue
exclusion and neutral red uptake [14, 15, 29, 30]. Six to eight
explants from each treatment group were used to determine
protein content and viability. Tubular hyperplasia was evaluated
by utilizing a modification of a previously described protocol for
bromodeoxyuridine (BrdU) uptake [31, 32]. At 96 hours of
incubation, 10 JiM BrdU (well in excess of media thymidine
content) was added to the media of all groups and explants were
harvested at 120 hours. Cellular uptake of BrdU was identified by
staining with alkaline phosphatase conjugated to a monoclonal
anti-BrdU antibody (Boehringer Mannheim, Indianapolis, IN,
USA). Following routine histologic preparation (see below) six to
ten, 3 JIM serial sections of intact explants were evaluated for
BrdU uptake, expressed as BrdU-positive cells per 500 cells
counted. Three to six explants from each treatment group were
used for determination of BrdU uptake.
Histology, immunohistology, and determination of segmental
nephron growth and differentiation
Following 120 hours of incubation, intact explants from all
control and treatment groups were assessed histologically. Tissue
was fixed in 3.5% paraformaldehyde in phosphate buffer (pH 7.4)
for 30 minutes at 4°C. Tissue was then washed, dehydrated
through graded acetone, and infiltrated and embedded with
ImmunobedTM plastic embedding medium (Polysciences, War-
rington, PA, USA). Sections were cut at 3 JiM on an ultramic-
rotome, mounted on glass slides, and stained with hematoxylin.
Segmental nephron growth and differentiation were quantitated
in each group by combining morphometric analysis with light
microscopy and immunohistologic techniques. Segmental growth
and differentiation were evaluated quantitatively by determining
the number of epithelial glomeruli, proximal tubules, and collect-
ing tubules formed under control and each set of treatment
conditions. Glomeruli were identified histologically as previously
described [14, 16, 30]. Proximal tubules were identified by staining
with the lectin Lotus tetragonolobus and collecting tubules were
identified by staining with the lectin Dolichos btflorus [16]. Undif-
ferentiated mesenchyme was identified by staining with antibody
to vimentin (Sigma) and differentiated epithelium was identified
by staining with antibody to cytokeratin (Sigma) [33]. The number
of epithelial glomeruli or specific immunostained tubular seg-
ments per explant was determined by established light micro-
scopic morphometric techniques using a standard test grid [34].
Intact explants were serially sectioned at 3 jiM, and, beginning
with a random start, specific structures were counted at 10 evenly
spaced intervals (approximately every 15 JtM) throughout the
explant. Serial sections were evaluated for specific structures in
three to six explants per group. These data were then evaluated
using a morphometric software program (QM 2000) based on
the Cavalieri method of volume estimate [34].
Statistical analysis
Data generated from the above assessments yielded a non-
parametric distribution, and are therefore expressed as mean
values with ranges. The significance of differences between treat-
ment group means was determined by the Wilcoxon rank sum test
[35]. Following statistical analysis, growth and differentiation data
generated by the treatment groups were expressed as a percent of
control to facilitate graphic presentation. Since there were no
statistical differences in any outcome parameters between groups
treated with EGF (15 ng/ml) or TGF-a (10 ng/ml), the figures
show only the data for the EGF-treated groups. EGF-R tyrosine
kinase inhibition achieved with either Tyrphostin B42 (0.1 JIM) or
genestein (5.5 jig/mI) resulted in no statistical differences between
these groups in any of the outcome parameters assessed, and the
figures therefore reflect only the data for the Tyrphostin B42-
treated groups.
Results
Organ culture morphology
Following 120 hours of culture, explants in all groups demon-
strated advanced glomerulogenesis and segment specific tubular
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Fig. 1. Explant moiphology following 120 hours of incubation. (A)
Control explant incubated in basal medium demonstrating organotypic
differentiaion with epithelial glomeruli and well-formed tubular
elements surrounding distal branches of the ureteric bud (magnification
75X). (B) Explant incubated with EGF (15 ng/ml) with numerous
tubular cystic lesions against a background of normal in vitro
nephrogenesis (magnification 95X). (C) Explant incubated with EUF
(15 ng/ml) demonstrating hyperplastic micropolyp-like lesion protruding
into cystic tubular lumen (magnification 500X). (D) Explant incubated
with EGF (15 nglml) and EOF-R monoclonal antibody (50 mg/mI) with
significantly decreased cyst formation and overall nephrogenesis similar
to controls, but with nodular condensations of blastemal cells
surrounding distal branches of the ureteric bud (magnification 75X).
(E) Explant incubated with EGF (15 nglml) and EGF-R monoclonal
antibody (50 mg/mI) demonstrating nodular blastemal hyperplasia
(magnification 285 x).
cytodifferentiation (Fig. 1). As previously described, control ex-
plants demonstrated advanced glomerular visceral epithelial and
tubular epithelial differentiation following 120 hours of culture
(Fig. 1A) E14, 15, 29, 30]. Treatment with either EGF (15 ng/ml)
or TGF-a (10 nglml) resulted in marked morphological differ-
ences in developing explants (Fig. 1B). There were numerous
cystic lesions localized to LTA-positive proximal tubules which
were lined with a hyperplastic tubular epithelium and formed
intraluminal micropolyp-like lesions in some areas (Fig. 1C) [14].
EGF and TGF-a induced hyperplastic proximal tubular cyst
formation against a background of normal in vitro organ culture
differentiation without morphological evidence of tubular damage
or epithelial toxicity. There were no distinguishable morphologi-
cal differences between explants treated with EGF or TGF-a
following 120 hours of incubation.
Receptor blockade
To assess the effectiveness of anti EGF-R (8506) as a blocking
antibody, competive ligand binding assay using 1251 labeled EGF
was utilized (see Methods). As shown in Figure 2, the addition of
anti EGF-R (8506) resulted in a 46% decrease in specific binding
of labeled EGF as compared to basal or control explants (no
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pre-treatment or addition of anti-EGF-R). The addition of
tyrphostin B42 had no effect on specific binding, yielding binding
levels similar to basal explants. Western analysis of receptor
autophosphorylation as shown in Figure 3 demonstrates marked
reduction in autophosphorylation of the receptor in explants
treated with either anti-EGF-R or tryphostin B42.
Receptor blockade of the EGF-R and its tyrosine kinase activity
at either the level of ligand-EGF-R binding by the addition of
EGF-R blocking antibody (50 nglml) or at the level of the
activated EGF-R tyrosine kinase by the addition of Tyrphos-
Fig. 4. Cystic inde.t Symbols are: ( ) EGF; () EGF + EGF-R AB; ()
EGF + TKI. The y-axis indicates the mean cystic index as determined by
morphometry (see text for details). Groups treated with EGF (15 ng/ml),
EGF + EGF-R monoclonal antibody (50 mg/mI), or EGF + a tyrosine
kinase inhibitor (Tyrphostin B42, 0.1 zM, or genestein 5.5 ig/ml) are
indicated along the x-axis. *significance when compared to controls (P <
0.01) and ** denotes significance when compared to the EGF-treated
group (P < 0.01). Bars indicate the SEM for each group.
tin B42 (0.1 jsM) or genestein (5.5 tg/ml) to EGF or TGF-c
supplemented medium resulted in significantly decreased cyst
formation with morphological features similar to that seen in
control explants (Fig. 1D). Well-defined epithelial glomeruli and
+ 170 tubular structures were present. Small cystic lesions which local-
ized to LTA-positive proximal tubules but were inconsistent
features persisted in some areas. However, in antibody or tyrphos-
tin treated explants there were nodular condensations of blast-
emal cells surrounding the distal branches of the ureteric bud
(Fig. 1E). These areas of nodular blastemal hyperplasia were
vimentin positive and cytokeratin negative (data not shown). In
the control explants, there were only small aggregates of vimentin
positive, cytokeratin negative undifferentiated mesenchymal cells
surrounding the tips of the branching ureteric bud. The morphol-
ogy of control explants incubated for 120 hours in basal medium
and Tyrphostin 1 (25 PM), Tyrphostin B42 (0.1 .rM), genestein
(5.5 gIml), or EGF-R monoclonal blocking antibody (50 ng/ml)
could not be differentiated from explants incubated in basal
medium alone, and there were no histological indications of
cytotoxicity.
Cystic index
The cystic index permits quantitation of morphological changes
seen in explant morphology (Fig. 4). The addition of EGF 15
nglml or TGF-a 10 nglml to basal medium resulted in a statisti-
cally significant increase in the proximal tubular cystic index from
a control value of 0. The addition of EGF-R antibody (50 mgfml)
or a tyrosine kinase inhibitor (Tyrphostin B42 0.1 tM or genestein
5.5 .tg/ml) to growth factor-supplemented basal medium resulted
+
Fig. 2. 125j binding. Symbols are: ( ) basal; () EGF + EGF-R AB; ()
EGF + TM. Ligand binding assay was performed to demonstrate the
specific inhibition of ligand receptor interaction by monoclonal antibody
treatment (8506). Following 96 hours of culture a 46% decrease in specific
ligand binding (normalized per sg of protein) of explants treated with
anti-EGF-R versus specific binding of basal explants was shown. Signif-
icance when compared to basal explants or tyrphostin B42 explants (P <
0.05). Treatment of explants with Tyrphostin B42 demonstrated no
significant difference from basal explants.
EGF EGF
BASAL EGF +
aEGF-R TKI
200—÷
97.4—±
Fig. 3. Tyrosine kinase inhibition. Western analysis of immunoprecipated
autophosphoiylated EGF-R demonstrates a marked reduction in auto-
phosphorylation of both antibody treated explants (lane 3) and Tyrphostin
B42 treated explants (lane 4) compared to explants treated with EGF
alone (lane 2).
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Fig. 5. Explant growth and tubular hyperplasia. The y-axis indicates per-
cent of control values. Groups treated with EGF ( ; 15 ng/ml), EGF +
EGF-R monoclonal antibody (; 50 mg/mI), or EGF + a tyrosine kinase
inhibitor (; Tyrphostin B42, 0.1 MM, or genestein 5.5 jig/mI) are iodicated
along the x-axis. *significance when compared to controls (P < 0.02) and
denotes significance when compared to the EGF-treated group (P <
0.05). Bars indicate the SEM for each group.
in a significant decrease in the proximal tubular cystic index as
compared to the growth factor-treated group. Negative control
groups consisting of basal medium to which either EGF-R
blocking antibody (50 mg/mi), Tyrphostin B42 (0.1 jiM), or genestein
(5.5 jig/mi) had been added were incubated for 120 hours. There
were no observable cysts in any of these groups.
Growth and hyperplasia
Viability was over 95% for the control group and all treatment
groups. Figure 5 illustrates explant protein content and tubular
hyperplasia of the various treatment groups as compared to the
control group. Growth factor supplementation (EGF 15 ng/ml or
TGF-a 10 ng/ml) produced a significant increase in explant
protein content and tubular hyperplasia when compared to the
control group following 120 hours of incubation. The addition of
EGF-R antibody (50 mg/ml) or a tyrosine kinase inhibitor (Tyr-
phostin B42 0.1 jiM or genestein 5.5 jig/mI) to growth factor-
treated explants caused significant decreases in both protein
content and tubular hyperplasia as compared to growth factor-
treated groups. inhibition of EGF-R tyrosine kinase activity
returned explant protein content and tubular hyperplasia to levels
which were not statistically different from the control group.
Negative control groups were incubated for 120 hours with basal
medium and either EGF-R blocking antibody (50 mg/ml), Tyr-
phostin B42 (0.1 rM), or genestein (5.5 jig/ml). There were uo
statistical differences in protein content or tubular hyperplasia
between any of these groups and the control group (data not
shown).
Segmental nephron growth and differentiation
Incubation for 120 hours with EGF (15 ng/ml) or TGF-a
(10 ng/ml) produced signficant decreases in the formation of
glomeruli and proximal tubular elements while significantly in-
Fig. 6. Segment specific nephron differentiation. The y-axis indicates per-
cent of control values. The formation of structural elements determined
morphometrically (see text for details). Abbreviations are: G, glomeruli;
PT, proximal tubules; CT, collecting tubule. Symbols are for groups
treated with EGF ( ; 15 ng/ml), EGF + EGF-R monoclonal antibody
(; 50 mg/nil), or EGF + a tyrosine kinase inhibitor (; Tyrphostin B42,
0.1 MM, or genestein 5.5 jig/ml) are indicated along the x-axis. *signifi..
cance when compared to controls (P C 0.05) and * *denotes significance
when compared the EGF-treated group (P C 0.02). Bars indicate the 5CM
for each group.
creasing collecting tubular structures as compared to the control
group (Fig. 6). EGF-R tyrosine kinase inhibition with either
EGF-R blocking antibody (50 mg/ml), Tyrphostin B42 (0.1 jiM),
or genestein (5.5 jig/mi) significantly attenuated these effects,
bringing the formation of glomerular, proximal tubular, and
collecting tubular structures back toward control values. Experi-
mental groups in which either EGF-R blocking antibody (50
mg/ml), Tyrphostin B42 (0.1 jiM), or genestein (5.5 jig/mI) had
been added to basal medium demonstrated no significant differ-
ences in segmental nephron growth and differentiation when
compared to controls.
Discussion
In murine metanephric organ culture, blockade of the EGF-R
or the EGF-R tyrosine kinase activity significantly inhibits the
effects of EGF and TGF-a on the developing metanephros. As
previously reported [81, EGF and its fetal form, TGF-a, induced
explant growth, epithelial hyperplasia, and proximal tubular cyst
formation in metanephric explants in the current study. Blockade
of the EGF-R with EGF-R blocking antibody significantly inhib-
ited all these effects. Inhibition of the EGF-R tyrosine kinase
activity with a synthetic tyrosine kinase inhibitor, either a tyrphos-
tin or genestein, also abolished the cystogenic and mitogenic
effects of EGF and TGF-a in metanephric organ culture. Numer-
ous studies have demonstrated that tyrosine kinase inhibitors can
inhibit protein phosphorylation associated with the EGF-R [21,
22, 36]. Tyrphostins are a family of synthetic protein tyrosine
kinase inhibitors which block EGF-dependent signal transduction
and EGF-dependent proliferation of transformed cells. In this
study, the tyrphostins used varied in specificity for inhibition of
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EGF-R autophosphorylation versus intracellular receptor sub-
strate phosphosylation. Advantages to their use include their
noncompetitive behavior with ATP and therefore reduced cyto-
toxicity and their water solubility and mild hydrophobicity result-
ing in enhanced penetration of cellular membranes. Tyrphostin
B42 is very specific for EGF-R autophosphorylation, and the IC50
for this function is 100- to 10,000-fold less than is necessary to
inhibit other receptor tyrosine kinases and serine/threonine ki-
nases [23]. Genestein is a competitive inhibitor with ATP and
noncompetitive inhibitor with intracellular receptor substrate, and
has been previously shown in preliminary studies to inhibit the
cystogenic and mitogenic effects of EGF in metanephric organ
culture [37, 38]. Blocking the EGF-R or its tyrosine kinase activity
resulted in nodular blastemal hyperplasia of undifferentiated
mesenchymal cells around the distal tips of the ureteric buds (Fig.
1E). It has been shown that EGF induces mesenchyme to
differentate into stroma, and suggested that EGF may act in an
autocrine manner to regulate the differentiation of epithelium and
interstitium from mesenchyme [39]. In the current study, blockade
of EGF-R tyrosine kinase activity resulted in areas of increased
undifferentiated mesenchyme which is consistent with these data.
It has been demonstrated that rat metanephroi produce small
amounts of TGF-a in organ culture and that TGF-a is necessary
for normal in vitro metanephric growth and nephrogenesis in this
system [40]. In the current study, there were no significant
differences in any of the outcome parameters assessed between
control explants and explants incubated with EGF-R blocking
antibody, Typhostin B42, or genestein alone. Although the pro-
duction of TGF-a was not measured in the current study, it is very
likely that small amounts are produced given the similarity
between the rat and murine organ culture systems. The concen-
tration of EGF-R blocking antibody used in the current study was
chosen because it was effective in significantly attentuating but not
completely abolishing the effects of EGF. Likewise, the concen-
trations of the tyrosine kinase inhibitors used were to achieve 50%
maximal effect. It is therefore possible that unlike the complete
inhibition of explant TGF-cs by anti-growth factor antibody in rat
culture [36], endogenous TGF-a was able to bind with enough
EGF-R to initiate the requisite signal transduction for normal
growth and nephrogenesis in the current study. This hypothesis is
supported by the fact that explant growth and viability progres-
sively decreased when concentrations of anti-EGF-R antibody
higher than 50 mglml were utilized in our in vitro system (data not
shown), and the detection of decreased, but measurable tyrosine
phosphorylation of EGF-R in explants treated with EGF and
either anti-EGF-R antibody or tyrophostin B42 (Fig. 3).
Previous studies have demonstrated that EGF induces de-
creased formation of glomerular and proximal tubular elements
and enhanced collecting tubule differentiation in murine meta-
nephric organ culture [8]. The current study confirms these
findings and also shows that inhibition of EGF-R tyrosine kinase
activity at either the level of the receptor or at the level of EGF-R
tyrosine kinase activity significantly attenuated these changes.
This suggests that the EGF-R plays a crucial role in segment
specific differentiation. A limitation in assessing segmental
nephron growth and differentiation in the current study is that
there is not a way to distinguish between increased numbers of
differentiated structures (that is, new nephron formation or
acquisition of lectin staining) versus increased growth of segments
which have already differentiated (that is, increased tubular length
in a lectin-positive segment). Therefore, the data do not represent
absolute numbers of specific structures per explant and are
meaningful only in relation to simultaneously cultured control
explants.
Findings of the current study support the hypothesis that EGF
plays a significant role in the processes of tubular cyst formation,
tubular hyperplasia, and segmental differentiation via the tyrosine
kinase activity of the EGF-R. Biologically, this is supported by the
abnormalities in EGF,TGF-a/EGF-R system demonstrated in
murine and human polycystic kidney disease. In a murine model
of autosomal recessive polycystic kidney disease, the cpk mouse,
both qualitative and quantitative abnormalities of EGF-R expres-
sion have been noted [41]. In cystic cpk collecting tubules, the
EGF-R is mislocated from the basolateral tubular epithelial cell
surface to the apical tubular epithelial cell surface. Further, the
cpk kidney has increased EGF-R mRNA and protein compared to
the normal C57 phenotype. In human ARPKD, a significant
population of cystic tubular segments demonstrate apical mislo-
cation of the EGF-R [42]. In addition to the abnormalities of
EGF-R expression demonstrated in cystic kidneys, mitogenic
concentrations of EGF-like peptides have been demonstrated in
the cyst fluid from both human and experimental cystic disease
[43—451. Finally, human ADPKD kidneys have increased mRNA
and protein levels of TGF-a and EGF-R [43, 46], and cultured
cyst wall-derived epithelial cells are hypersensitive to EGF [43].
These studies support the hypothesis that the presence of mito-
genic concentrations of EGF and TGF-a peptides in cyst fluid
coupled with abnormal EGF-R expression in cystic tubular epi-
thelium mediate epithelial hyperplasia and tubular cyst formation
in experimental and human PKD.
The EGF/TGF-a/EGF-R autocrine-paracrine cycle of hyper-
plasia in PKD is a potential target of specific pharmacotherapy. By
analogy, psoriasis is associated with the overexpression of the
TGF-a gene [47]. Sustained autocrine activation of the EGF-R by
TGF-a on keratinocytes plays a key role in the development and
maintenance of this condition. Tyrphostins block the proliferation
of human keratinocytes, and the inhibition of cell proliferation
parallels the inhibition of DNA sythesis and EGF-induced
tyrosine phosphorylation [21]. Drawing on this experimental
background, preliminary clinical trials have demonstrated the
efficacy of topical tyrphostins as medical therapy for psoriasis [26].
If appropriate delivery systems can be developed, similar phar-
macological manipulation of the EGFITGF-aIEGF-R axis via
antireceptor antibodies or compounds such as tyrphostins could
provide specific therapy to prevent progressive tubular cyst en-
largement in human cystic kidney diseases.
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